M1 Kliniken AG publishes figures for the 1st half of 2021: stable business development despite continued Corona burdens

- Group revenue rises to just under EUR 165 million (EUR 37 million in H1-2020)

- Consolidated EBITDA amounts to EUR 9.9 million (previous year: EUR 1.7 million); EBIT amounts to EUR 7.1 million (previous year: EUR -0.05 million)

- Beauty: Significant increase in treatment and sales figures; Corona-related 'idle capacity' due to vaccination intervals

Berlin, 25.08.2021 - M1 Kliniken AG (ISIN: DE000A0STSQ8) announces financial figures for the first half of 2021. The consolidated revenue of the M1 Group in the first half of the financial year 2021 increased by approx. 420 % compared to the previous year to now almost EUR 165 million (previous year: EUR 37 million). HAEMATO AG (without M1 Aesthetics), which was not yet consolidated in the same period of the previous year, accounted for sales of just under EUR 134 million.

Business performance in the Beauty segment has normalised significantly compared to the previous year. With approx. 82 thousand treatments in the second quarter, the value from the first quarter of 2021 (81 Tsd.) was attained again. However, due to the progressing vaccination campaign in the core age segment of M1 and mandatory time intervals between vaccinations and treatments, M1 could not exploited the full potential of its treatment capacity. In addition, some of the foreign locations were again affected by lockdowns. Sales in the Beauty segment increased to EUR 22.0 million (previous year: EUR 15.9 million - restatement for Q1-2021: EUR 11.6 million / Q1-2020: EUR 9.4 million).

In the trading segment, HAEMATO AG generated sales of approximately EUR 25 million with the COVID antigen rapid tests. Test sales concentrated at the beginning of the second quarter. Due to the significant oversupply of rapid tests and rapidly falling sales prices, the company has largely withdrawn from this business segment and does not expect further substantial sales in the course of fiscal year 2021.

EBITDA of M1 Kliniken AG totalled EUR 9.9 million in H1-2021 (previous year: EUR 1.7 million), EBIT amounted to EUR 7.1 million (previous year: EUR -0.05 million). The previous year was marked by the first wave of the Corona pandemic with the closure of all sites from 23 March 2020 until mid-May 2020. The earnings trend at the foreign sites improved significantly. The Group generated negative EBIT of EUR 0.3 million in this area in the first half of 2021; in the first half of 2020 a negative EBIT of EUR 1.4 million was recorded. However, the company does not expect a significant contribution to group earnings from M1's foreign activities in the foreseeable future. Investments into the market presence and brand strength in local markets will influence the earnings, but will build the foundation for the successful development of the Group in the medium to long term.

"Even if this is not yet reflected in the figures for the first half of the year, we have set course again for more growth. With four new locations in Germany, we have optimised regional coverage in our home market. Abroad and also in Germany, we are working on a number of further locations, so that the target of 50 specialist centres by the end of the year is within reach. With this, we are creating the basis for the sales growth of the M1 group in the coming years." - says the CEO of M1 Kliniken AG, Dr. Walter von Horstig.

The detailed report for the first half of 2021 will be available for download from the Company's website https://www.m1-kliniken.de/aktie/geschaeftsberichte.html as of 1 September 2021.

About M1 Kliniken AG

M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical area, the group of companies offers products and services with the highest quality standards. Under the "M1 Med Beauty" brand, beauty medical treatments are currently offered at more than 40 specialist centres. In this context, the M1 Schlossklinik for plastic and aesthetic surgery in Berlin, with six operating theatres and 35 beds, is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been pushing ahead with internationalisation and is currently also active in Austria, Switzerland, the Netherlands, England, Croatia and Australia. With its investment in HAEMATO AG, M1 Kliniken AG is also in a position to exploit the sales and earnings potential of its treatment products in the medical-aesthetic field.